|
Facebook
Twitter
Linkedin
|
 |
 |
 |
 |
Healthcare Company News 
Toshiba Medical Systems Corporation Toshiba Receives FDA clearance for Vantage Titan MR system
Toshiba Medical Systems Corporation Toshiba Receives FDA clearance for Vantage Titan MR system
Toshiba Receives FDA clearance for Vantage Titan MR system
Monday, 29 November 1999 19:00 | 
| Company News - Toshiba Medical Systems Corporation |
Toshiba America Medical Systems, Inc., announced FDA clearance for the new open-bore 1.5T Vantage Titan magnetic resonance (MR) system.
Toshiba America Medical Systems, Inc., announced FDA clearance for the new open-bore 1.5T Vantage Titan magnetic resonance (MR) system. With this clearance, Toshiba is on schedule to make the system commercially available in the first quarter of 2008. The open-bore of the Vantage Titan is 18 per cent larger than other 1.5T systems on the market, featuring a large 71-centimeter patient aperture.
"Toshiba's Vantage Titan is now one of the most powerful MR units available with a 30/130 gradient platform," said Bob Giegerich, director, MR Business Unit, Toshiba. "It is a dramatic improvement over traditional open-bore 1.5T MR systems and offers the largest and widest bore available with a significant reduction in noise."
The Vantage Titan's large clinical field-of-view is unique for this bore size and produces high-quality images without compromising homogeneity or overall imaging performance. The system also features Toshiba's patented PianissimoTM noise reduction technology, which creates a better imaging experience for all patients.
The Vantage Titan MR system also takes advantage of Toshiba's proprietary, contrast-free MRA techniques - Fresh Blood Imaging (FBI), Contrast-free Improved Angiography (CIA), Time-Spatial Labeling Inversion Pulse (Time-SLIP) and Time-Slip Angiography (TSA). Contrast-free imaging is particularly important because gadolinium, the most common contrast agent used for magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) exams, has been directly linked to a sometimes fatal disease that occurs in patients with renal insufficiency, called Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD).
"Toshiba's Vantage Titan is now one of the most powerful MR units available with a 30/130 gradient platform," said Bob Giegerich, director, MR Business Unit, Toshiba. "It is a dramatic improvement over traditional open-bore 1.5T MR systems and offers the largest and widest bore available with a significant reduction in noise."
The Vantage Titan's large clinical field-of-view is unique for this bore size and produces high-quality images without compromising homogeneity or overall imaging performance. The system also features Toshiba's patented PianissimoTM noise reduction technology, which creates a better imaging experience for all patients.
The Vantage Titan MR system also takes advantage of Toshiba's proprietary, contrast-free MRA techniques - Fresh Blood Imaging (FBI), Contrast-free Improved Angiography (CIA), Time-Spatial Labeling Inversion Pulse (Time-SLIP) and Time-Slip Angiography (TSA). Contrast-free imaging is particularly important because gadolinium, the most common contrast agent used for magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) exams, has been directly linked to a sometimes fatal disease that occurs in patients with renal insufficiency, called Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD).
